文献速递细菌感染、耐药与抗菌药物医院感染防控新发突发、热带与寄生虫病

从抗菌药物耐药监测中生成可行动数据:弗莱明基金国际经验启示

Generating Actionable Data From Antimicrobial Resistance Surveillance: Insights From the Fleming Fund's International Experience.
PubMed 文献 · Clin Infect Dis · 2026-01-01

本文基于弗莱明基金2015年起在非洲和亚洲通过同一健康方法强化抗菌药物耐药监测的项目经验、国家实施证据及已发表文献,描述其如何将监测落地、评估数据数量与质量贡献、识别实施挑战并思考未来全球监测策略。基金投资实验室基础设施、人力、质量保证、数据系统、治理和数据使用,使常规细菌学与药敏试验显著增长,但进展不均且受基础设施、供应链、人力流动、数据碎片化、临床-实验室衔接弱、代表性有限和长期融资不确定等因素制约。

要点

  • 弗莱明基金通过实验室、人力、质量保证、数据系统、治理和数据使用综合投资强化中低收入国家抗菌药物耐药监测。
  • 投资使常规细菌学与药敏试验、参考实验室能力、外部质量评估参与和向全球监测系统报告显著增长。
  • 进展不均且面临基础设施、供应链、人力流动、数据碎片化、临床-实验室衔接弱和融资不确定等挑战。

核心结论

  • 在中低收入国家强化抗菌药物耐药监测是可行的,但需要持续、系统性的投资。
  • 未来策略应优先整合临床诊疗、加强数字与分析能力、扩大诊断可及性和国内融资,以确保高质量数据被生成、共享并转化为行动。

研究设计与样本

  • 本文基于弗莱明基金项目经验、国家实施证据和已发表文献,描述其如何落地抗菌药物耐药监测并评估贡献与挑战。
  • 弗莱明基金由英国政府于2015年设立,通过同一健康方法在非洲和亚洲强化抗菌药物耐药监测。

主要发现

  • 在受支持国家,投资使常规细菌学和抗菌药物敏感性试验大幅增长,参考与监测实验室能力增强,外部质量评估参与增加,向世界卫生组织全球抗菌药物耐药与使用监测系统的报告扩大。
  • 项目还支持补充监测方法,包括抗菌药物使用与消耗数据,并在部分场景支持疾病负担和基因组监测。
  • 进展不均,且仍易受脆弱基础设施、采购与供应链瓶颈、人力流动、数据系统碎片化、临床-实验室衔接弱、代表性有限和长期融资不确定的影响。

临床怎么用

  • 临床与实验室应加强衔接,使药敏数据可被临床读取并用于抗感染决策。
  • 应优先建设数字与分析能力,扩大诊断可及性,并推动国内融资以维持监测数据质量与可持续性。

局限性

  • 进展不均且受脆弱基础设施、采购与供应链瓶颈、人力流动、数据系统碎片化、临床-实验室衔接弱、代表性有限和长期融资不确定等因素制约。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antimicrobial resistance (AMR) is a major global health threat, with the greatest burden falling on low- and middle-income countries (LMICs) also challenged with limited surveillance capacity. The UK Government's Fleming Fund was established in 2015 to strengthen AMR surveillance across Africa and Asia through a One Health approach. This paper draws on program experience, country implementation evidence, and published literature to describe how the Fleming Fund operationalized AMR surveillance, assess its contribution to the quantity and quality of surveillance data, identify key implementation challenges, and consider implications for future global surveillance strategies. The Fleming Fund combined investments in laboratory infrastructure, workforce development, quality assurance, data systems, governance, and data use. Across supported countries, these investments enabled substantial growth in routine bacteriology and antimicrobial susceptibility testing, strengthened reference and surveillance laboratory capacity, increased participation in external quality assessment, and expanded reporting to the World Health Organization's Global Antimicrobial Resistance and Use Surveillance System. The program also supported complementary surveillance approaches, including antimicrobial use and consumption data and, in some settings, burden-of-disease and genomic surveillance. Progress, however, has been uneven and remains vulnerable to fragile infrastructure, procurement and supply chain bottlenecks, workforce turnover, fragmented data systems, weak clinical-laboratory interfaces, limited representativeness, and uncertain long-term financing. The Fleming Fund experience shows that strengthening AMR surveillance in LMICs is feasible, but requires sustained, system-wide investment. Future strategies should prioritize integration with clinical care, stronger digital and analytical capacity, broader diagnostic access, and domestic financing to ensure that high-quality AMR data are generated, shared, and translated into action.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Gupta-Wright A, Adeleke SY, Adetunji V, et al. Generating Actionable Data From Antimicrobial Resistance Surveillance: Insights From the Fleming Fund's International Experience. Clin Infect Dis. 2026. PMID: 42895838. doi:10.1093/cid/ciag497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。